Literature DB >> 23042077

Creation of a six-fingered artificial transcription factor that represses the hepatitis B virus HBx gene integrated into a human hepatocellular carcinoma cell line.

Xinghui Zhao1, Zhanzhong Zhao, Junwei Guo, Peitang Huang, Xudong Zhu, Xiaowei Zhou, Zhixin Yang, Lixia Zhao, Long Xu, Junjie Xu, Ling Fu, Jun Zhang, Xiaopeng Zhang, Yunzhu Dong, Gang Huang, Qianfei Wang, Bo Li, Xiaohong Song, Xiuxu Yang, Shuling Liu, Shaoqiong Yi, Ting Yu, Changming Yu, Lihua Hou, Jianmin Li, Wei Chen.   

Abstract

Chronic hepatitis B virus (HBV) infection is an independent risk factor for the development of hepatocellular carcinoma (HCC). The HBV HBx gene is frequently identified as an integrant in the chromosomal DNA of patients with HCC. HBx encodes the X protein (HBx), a putative viral oncoprotein that affects transcriptional regulation of several cellular genes. Therefore, HBx may be an ideal target to impede the progression of HBV infection-related HCC. In this study, integrated HBx was transcriptionally downregulated using an artificial transcription factor (ATF). Two three-fingered Cys2-His2 zinc finger (ZF) motifs that specifically recognized two 9-bp DNA sequences regulating HBx expression were identified from a phage-display library. The ZF domains were linked into a six-fingered protein that specified an 18-bp DNA target in the Enhancer I region upstream of HBx. This DNA-binding domain was fused with a Krüppel-associated box (KRAB) transcriptional repression domain to produce an ATF designed to downregulate HBx integrated into the Hep3B HCC cell line. The ATF significantly repressed HBx in a luciferase reporter assay. Stably expressing the ATF in Hep3B cells resulted in significant growth arrest, whereas stably expressing the ATF in an HCC cell line lacking integrated HBx (HepG2) had virtually no effect. The targeted downregulation of integrated HBx is a promising novel approach to inhibiting the progression of HBV infection-related HCC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23042077     DOI: 10.1177/1087057112463066

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  5 in total

Review 1.  Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus.

Authors:  Abdullah Ely; Buhle Moyo; Patrick Arbuthnot
Journal:  Mol Ther       Date:  2016-02-26       Impact factor: 11.454

Review 2.  Progress and prospects of engineered sequence-specific DNA modulating technologies for the management of liver diseases.

Authors:  Samantha A Nicholson; Buhle Moyo; Patrick B Arbuthnot
Journal:  World J Hepatol       Date:  2015-04-28

Review 3.  The Role of Hepatitis B Core-Related Antigen.

Authors:  Takako Inoue; Yasuhito Tanaka
Journal:  Genes (Basel)       Date:  2019-05-09       Impact factor: 4.096

Review 4.  Progress and Prospects of Anti-HBV Gene Therapy Development.

Authors:  Mohube B Maepa; Ilke Roelofse; Abdullah Ely; Patrick Arbuthnot
Journal:  Int J Mol Sci       Date:  2015-07-31       Impact factor: 5.923

Review 5.  Gene Therapy for Chronic HBV-Can We Eliminate cccDNA?

Authors:  Kristie Bloom; Mohube Betty Maepa; Abdullah Ely; Patrick Arbuthnot
Journal:  Genes (Basel)       Date:  2018-04-12       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.